Moderna, Inc. $MRNA Shares Sold by V Square Quantitative Management LLC

Posted by Brenda Bartman on Oct 18th, 2026

V Square Quantitative Management LLC decreased its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 56.0% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 2,877 shares of the company’s stock after selling 3,655 shares during the quarter. V Square Quantitative Management LLC’s holdings in Moderna were worth $554,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Cohen Klingenstein LLC purchased a new position in shares of Moderna in the 3rd quarter valued at $404,000. PFG Private Wealth Management LLC bought a new position in shares of Moderna in the 3rd quarter worth $473,000. State of Alaska Department of Revenue raised its position in shares of Moderna by 1.7% in the 3rd quarter. State of Alaska Department of Revenue now owns 35,174 shares of the company’s stock worth $6,773,000 after acquiring an additional 573 shares in the last quarter. WealthPlan Investment Management LLC bought a new position in shares of Moderna in the 3rd quarter worth $229,000. Finally, Mather Group LLC. lifted its stake in shares of Moderna by 2.0% during the 3rd quarter. Mather Group LLC. now owns 7,756 shares of the company’s stock worth $1,494,000 after purchasing an additional 152 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Upcoming melanoma and other cancer-vaccine data remain the main bullish catalyst. Earlier positive results from Moderna’s personalized cancer-vaccine collaboration with Merck have increased expectations that new data could support the pipeline and help sustain the stock’s gains. Merck and Moderna cancer vaccine strategy
Positive Sentiment: Investor interest has also been supported by strong momentum, healthcare-sector fund flows and optimism that Moderna’s pipeline could diversify the business beyond COVID-19 vaccines. Moderna rallies as money rotates into healthcare
Neutral Sentiment: President Stephen Hoge sold a combined 78,369 shares in transactions conducted under a pre-arranged Rule 10b5-1 plan. Although the sales may weigh on sentiment, they represented only a small portion of his remaining holdings and were not discretionary trades made during the current move. Moderna insider trading filing
Neutral Sentiment: A study comparing the stability of three mRNA vaccines in human blood may provide useful scientific context for the platform, but it does not appear to offer an immediate change to Moderna’s revenue outlook or valuation. mRNA vaccine stability study
Negative Sentiment: Profit-taking has intensified after Moderna became one of the market’s strongest performers, with analysts cautioning that the stock’s valuation now depends heavily on successful pipeline execution. Goldman Sachs raised its target to $137 but retained a Neutral rating, leaving the target substantially below recent trading levels. Moderna valuation debate
Negative Sentiment: The broader selloff in vaccine stocks, including declines in Novavax and BioNTech, has added sector-wide pressure. Investors are also wary of Moderna’s continuing losses and negative cash flow while awaiting the cancer-data catalyst. Vaccine-stock selloff

Analysts Set New Price Targets

MRNA has been the subject of a number of analyst reports. Jefferies Financial Group restated a “hold” rating and set a $150.00 price objective (up from $60.00) on shares of Moderna in a research note on Wednesday, August 19th. CLSA upgraded Moderna to an “outperform” rating in a research note on Friday, August 28th. Loop Capital set a $135.00 target price on shares of Moderna in a report on Wednesday, August 19th. Morgan Stanley boosted their target price on shares of Moderna from $89.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. Finally, Wolfe Research raised shares of Moderna from an “underperform” rating to a “peer perform” rating in a research report on Tuesday, August 25th. Seven research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and an average target price of $101.45.

View Our Latest Report on MRNA

Insiders Place Their Bets

In other Moderna news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the sale, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 39,145 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $220.72, for a total value of $8,640,084.40. Following the sale, the president owned 1,636,565 shares in the company, valued at approximately $361,222,626.80. The trade was a 2.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is owned by company insiders.

Moderna Trading Down 7.8%

NASDAQ:MRNA opened at $218.01 on Friday. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $242.29. The firm has a fifty day simple moving average of $156.66 and a 200-day simple moving average of $90.88. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $87.04 billion, a P/E ratio of -27.29 and a beta of 1.09.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. During the same period in the previous year, the company earned ($2.13) earnings per share. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities research analysts anticipate that Moderna, Inc. will post -6.11 earnings per share for the current year.

Moderna Profile

(Free Report)

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.